Blood & Marrow Clinical Trials Network- Hutchinson Center as Core Clinical Site

血

• 批准号: 10430215
• 负责人: FREDERICK APPELBAUM
• 金额: $ 5.94万
• 依托单位: FRED HUTCHINSON CANCER CENTER
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-04-01 至 2024-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10430215
• 关键词: Blood; Marrow; Clinical; Trials; Network

Project Summary/Abstract Over the last 15 years, the BMT CTN has effectively addressed key issues in HCT, including donor selection, choice of preparative regimens, prevention of post-transplant infection, prevention and treatment of graft- versus-host disease and the indications for HCT in the treatment of specific diseases, through the conduct of 37 clinical trials. The Fred Hutch Transplant Program has played an important role in the success of the BMT CTN since its inception, serving as one of its Core Clinical Centers. There are a number of features of the Fred Hutch Transplant Program that enhances its value as a Core Clinical Center. (1) The volume of clinical activity at the Hutch allows us to successfully recruit and enroll patients on BMT CTN clinical trials, including patients with rare diseases. The Hutch’s performance in reaching its BMT CTN accrual targets over the last four year has been rated by the BMT CTN as “outstanding.” (2) Our long and deep experience with HCT provides outstanding clinical outcomes. For the past 3 years running, we have exceeded the 95% confidence limits for survival as calculated by the center-specific outcomes measures of the Center for International Blood and Marrow Transplant Research (CIBMTR). (3) The faculty of the Fred Hutch Transplant Program includes a large number of investigators, all focused on various aspects of HCT. The breadth and depth of this group whose NIH funding includes 6 Program Projects, 26 RO1s, and numerous other awards, helps insure that we will continue to provide important scientific contributions to the network. Each year for the last 4 years, our group has been rated as “outstanding” by the BMT CTN for our scientific and administrative efforts. (4) The Fred Hutch has extensive experience with novel cell therapies including stem cell expansion, genetic engineering of T cells, and correction of inborn errors, which are areas of specific interest noted by the NHLBI and the NCI. (5) The faculty of the Fred Hutch have enthusiastically collaborated with other members of the BMT CTN to help achieve the networks research goals over the past funding periods and is committed to continuing to do so.

项目摘要/摘要 在过去的15年中，BMT CTN有效地解决了HCT中的关键问题，包括捐助者选择， 选择准备方案，预防移植后感染，预防和治疗移植 与宿主疾病相对于宿主疾病以及通过进行HCT的指示，通过进行特定疾病的治疗 37个临床试验。 Fred Hutch移植计划在BMT的成功中发挥了重要作用 CTN自成立以来，是其核心临床中心之一。弗雷德有许多功能 Hutch移植程序可增强其作为核心临床中心的价值。 （1）临床活动的体积 在厨具上，我们能够成功招募和入学患者参加BMT CTN临床试验，包括患者 患有罕见疾病。在过去的四年中，该厨具在达到其BMT CTN核心目标方面的表现 BMT CTN被评为“杰出”。 （2）我们在HCT提供的漫长而深厚的经验 出色的临床结果。在过去的3年中，我们超过了95％的信心限制 根据中心特定结果的国际血液中心措施计算的生存 骨髓移植研究（CIBMTR）。 （3）Fred Hutch移植计划的教职员工包括一个大型 研究人员的数量都集中在HCT的各个方面。这个小组的广度和深度 NIH资金包括6个计划项目，26个RO1和许多其他奖项，有助于确保我们将 继续为网络提供重要的科学贡献。在过去的四年中，每年我们的小组 BMT CTN将我们的科学和行政努力评为“杰出”。 （4）弗雷德 Hutch在新型细胞疗法中具有丰富的经验，包括干细胞膨胀，基因工程 T细胞以及对先天误差的校正，这是NHLBI和NCI指出的特定感兴趣的领域。 （5）弗雷德·哈奇（Fred Hutch）的教职员工与BMT CTN的其他成员进行了热情合作 在过去的资金期间帮助实现网络研究目标，并致力于继续做 所以。